Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Golden Cariboo (CSE:GCC) (OTC:GCCFF) Expands Gold Footprint in BC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Aclaris Therapeutics Inc ACRS

Healthcare Biotechnology
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases... see more

Current News (NDAQ:ACRS)

Aclaris Therapeutics to Participate in Two February Healthcare Conferences

GlobeNewswire 12 days ago

Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

GlobeNewswire January 27, 2026

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

GlobeNewswire January 12, 2026

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

GlobeNewswire January 6, 2026

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

GlobeNewswire December 19, 2025

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire November 25, 2025

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2025

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

GlobeNewswire October 29, 2025

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025

GlobeNewswire September 30, 2025
View More News ››

Opinion & Analysis (NDAQ:ACRS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ACRS)

Using technical analysis for this stock.

It is signalling a big uptrend for shareholders today and tomorrow so good luck to all
coolfooldumbguy - July 30, 2025
View more Bullboard ››

Sorrento Resources Ltd.

Sorrento Resources Ltd.

Sorrento is engaged in acquisition, exploration, and development of mineral property assets in Canada. Sorrento’s objective ...
View More »

Podcasts